why am i so hungry on retatrutide Still a Retatrutide? You Are Reading the Wrong Signal Retatrutide is part of a

Am J Physiol Endocrinol Metab 300:E1038E1046

Dahlberg, S.E., Sandler, A.B., Brahmer, J.R., Schiller, J.H

Patients seeking a safer, reversible alternative to surgery Those with multiple metabolic conditions Individuals preferring outpatient options with faster recovery Whats New in Bariatric Endoscopy in 2025: Technology, Research, and Global Trends New technologies and techniques Enhanced suturing devices for quicker, more reliable ESG procedures Robotic-assisted endoscopy for greater precision and reduced operator fatigue AI in endoscopy for real-time feedback and outcome prediction Expanded indications Use in lower BMI patients with metabolic syndrome Preventive therapy in pre-diabetic individuals Broader global adoption through simplified training modules Improved multidisciplinary care Integration with digital coaching and remote patient monitoring Customized GLP-1 dosage and timing protocols Comprehensive psychological and nutritional support Clinical research and evidence Long-term trials demonstrating durability of combination therapy Real-world registries confirming low complication rates and sustained benefits ESG and GLP-1 Therapy at Bumrungrad A Safer, More Effective Future for Weight Loss As 2025 progresses, the combination of Endoscopic Sleeve Gastroplasty and GLP-1 therapy stands as a transformative solution for obesity and metabolic syndrome

Congratulations to all involved

Key Takeaway: Liposomal delivery acts like a protective "delivery vehicle," allowing glutathione to bypass digestive breakdown and reach the cells where it is needed most

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025